An obesity drug deep-dive, and peptides move mainstream
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Readout LOUD podcast episode covers new obesity treatments, the BPC‑157 peptide’s rise, recent ADA obesity data, a record IPO, and major biotech deals.
- Sara Talpos reports on BPC‑157’s journey from a Croatian lab to Reddit bodybuilding forums and FDA scrutiny.
- American Diabetes Association meeting provided obesity data discussed in the episode.
- AstraZeneca highlighted its GLP‑1 pill as a notable obesity treatment.
- Boehringer Ingelheim discussed its obesity candidate in the episode.
- Lilly introduced a new weight loss medication.
- GSK announced its acquisition of Nuvalent and noted Johnson & Johnson’s purchase of Firefly Bio.
Why it matters: The episode shows that obesity treatment is drawing massive capital, as evidenced by a record IPO and high‑profile acquisitions, which benefits biotech firms and patients seeking new therapies, while pushing regulators to evaluate novel peptides like BPC‑157, and underscores the FDA’s growing interest in peptide‑based drugs, potentially accelerating approval pathways.
